Retrospective large study looking at sotrovimab used on Covid patients had a 8% decreased risk of getting Long Covid. Their definition of Long Covid is "≥ 1 of 26 PASC symptoms ≥ 30 days after the first COVID-19 diagnosis"
link.springer.com/article/10.1...
Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data - Infection
Purpose To assess the impact of early sotrovimab treatment versus no treatment on the risk of developing post-acute sequelae of COVID-19 (PASC; long COVID) in patients (age ≥ 12 years) with COVID-19 a...
